XBiotech Inc (NASDAQ:XBIT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday. The firm presently has a $10.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 19.33% from the stock’s current price.

According to Zacks, “XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States. “

Separately, Noble Financial restated a “hold” rating and issued a $13.00 target price on shares of XBiotech in a research note on Friday, April 21st.

XBiotech (NASDAQ:XBIT) opened at 8.38 on Friday. The company’s market cap is $295.73 million. The firm’s 50-day moving average price is $12.40 and its 200 day moving average price is $12.83. XBiotech has a 52-week low of $8.00 and a 52-week high of $25.00.

COPYRIGHT VIOLATION NOTICE: “XBiotech Inc (XBIT) Upgraded at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/20/xbiotech-inc-xbit-upgraded-at-zacks-investment-research.html.

A number of institutional investors have recently made changes to their positions in XBIT. State Street Corp raised its position in shares of XBiotech by 6.9% in the fourth quarter. State Street Corp now owns 285,898 shares of the biopharmaceutical company’s stock worth $2,893,000 after buying an additional 18,352 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of XBiotech during the fourth quarter worth $103,000. Teachers Advisors LLC raised its position in shares of XBiotech by 6.8% in the fourth quarter. Teachers Advisors LLC now owns 27,619 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 1,759 shares in the last quarter. Capital Impact Advisors LLC acquired a new position in shares of XBiotech during the first quarter worth $862,000. Finally, JPMorgan Chase & Co. raised its position in shares of XBiotech by 670.5% in the first quarter. JPMorgan Chase & Co. now owns 24,840 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 21,616 shares in the last quarter. Institutional investors and hedge funds own 10.14% of the company’s stock.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

12 Month Chart for NASDAQ:XBIT

Get a free copy of the Zacks research report on XBiotech (XBIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for XBiotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.